Combining VISTA inhibitors with anti–CTLA-4 or anti–PD-1 antibodies overcomes adaptive resistance mechanisms and leads to robust tumor regression in murine melanoma models by reducing Treg frequencies and increasing granzyme B+ cytotoxic T lymphocytes in the tumor (171, 173). Here, CTLA4 is linked to neoplasm.